LNTHLantheus Holdings, Inc.
In Vitro & In Vivo Diagnostic Substances
- Revenue
- $1.5B
- 0.5% YoY
- Operating margin
- 20.2%
- 32% YoY
- EBITDA
- $311M
- 32% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -0.1×
- −$23M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear167% of net incomeCash flow under 80% of net income
- Dilutive SBCClear6% of revenueOver 10% of revenue
- Payouts exceed cash flowClear77% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear10% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $425M | $935M | $1.3B | $1.5B | $1.5B | 0.5% |
| Operating income | −$61M | $36M | $365M | $457M | $311M | 32% |
| Net income | −$71M | $28M | $327M | $312M | $234M | 25% |
| Operating cash flow | $54M | $282M | $305M | $545M | $390M | 28% |
| Capex | $0 | $260M | $45M | — | — | |
| Stock-based comp | $16M | $29M | $51M | $76M | $86M | 12% |
| Buybacks | $0 | $75M | $0 | $100M | $300M | 200% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.